Company Shares of CEPHEID (NASDAQ:CPHD) Rally 0.63%

On a relative basis, the stock has outperformed the S&P 500 by 16.27% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.63% in the last 1 week, and is up 18.15% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The company shares have dropped -44.67% from its 1 Year high price. On Jul 20, 2015, the shares registered one year high at $63.69 and the one year low was seen on May 6, 2016. The 50-Day Moving Average price is $29.21 and the 200 Day Moving Average price is recorded at $31.14.

The stock has recorded a 20-day Moving Average of 12.27% and the 50-Day Moving Average is 16.71%.


CEPHEID (NASDAQ:CPHD): stock turned positive on Friday. Though the stock opened at $31.7, the bulls momentum made the stock top out at $33.46 level for the day. The stock recorded a low of $31.69 and closed the trading day at $33.4, in the green by 6.47%. The total traded volume for the day was 726,820. The stock had closed at $31.37 in the previous days trading.

In an insider trading activity, The Securities and Exchange Commission has divulged that Campbell Scott A., officer (Corporate VP & CRO) of Cepheid, had unloaded 2,058 shares at an average price of $27.9 in a transaction dated on May 3, 2016. The total value of the transaction was worth $57,418.

Cepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the clinical market and non-clinical markets. Its systems enable molecular testing for organisms and genetic-based diseases. Molecular testing involves various time-intensive steps, including sample preparation, DNA amplification and detection. The Companys systems integrate these steps and analyze biological samples in test cartridges. Its primary offering is the GeneXpert system, which integrates sample preparation in addition to DNA amplification and detection, serves reference laboratories and hospital central laboratories to satellite testing locations, such as emergency departments and intensive care units within hospitals, as well as physician offices and other alternate site laboratories. It also offers the SmartCycler system, which integrates DNA amplification and detection to allow rapid analysis of a sample.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.